Literature DB >> 8274616

Antifungal susceptibility testing of yeasts: a brief overview.

D J Sheehan1, A Espinel-Ingroff, L S Moore, C D Webb.   

Abstract

Antifungal susceptibility testing of yeasts has lacked reproducibility because of the absence of universally accepted guidelines. The major sources of variation in susceptibility testing have been attributed to the choice of medium and pH, inoculum preparation and size, incubation temperature and time, and end-point criteria. These parameters have been addressed by the National Committee for Clinical Laboratory Standards (NCCLS) Subcommittee on Antifungal Susceptibility Testing, and proposed guidelines have recently been published. Although major advances in antifungal susceptibility testing have been achieved, particularly through the efforts of the NCCLS subcommittee, the results of studies to date do not support a correlation between the results of in vitro susceptibility testing and in vivo response. Routine antifungal susceptibility testing of yeasts should therefore be discouraged until the methodology is standardized such that it predicts clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8274616     DOI: 10.1093/clinids/17.supplement_2.s494

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Comparison of a new colorimetric assay with the NCCLS broth microdilution method (M-27A) for antifungal drug MIC determination.

Authors:  R K Li; C M Elie; G E Clayton; M A Ciblak
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Effect of fluconazole on viability of Candida albicans over extended periods of time.

Authors:  P G Sohnle; B L Hahn; M D Erdmann
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  Effect of prolonged fluconazole treatment on Candida albicans in diffusion chambers implanted into mice.

Authors:  Peter G Sohnle; Beth L Hahn
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

4.  L-proline as a nitrogen source increases the susceptibility of Saccharomyces cerevisiae S288c to fluconazole.

Authors:  C A Stella; R Costanzo; H I Burgos; D A Saenz; R D Venerus
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

5.  Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from oral cavities of AIDS patients.

Authors:  A M Tortorano; M A Viviani; F Barchiesi; D Arzeni; A L Rigoni; M Cogliati; P Compagnucci; G Scalise
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

Review 6.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

7.  The antifungal activities of some 6-[N-(halophenyl)amino]-7-chloro-5,8-quinolinediones against Candida species.

Authors:  C K Ryu; D H Kim
Journal:  Arch Pharm Res       Date:  1994-12       Impact factor: 4.946

8.  Investigating spectrum of biological activity of 4- and 5-chloro-2-hydroxy-N-[2-(arylamino)-1-alkyl-2-oxoethyl]benzamides.

Authors:  Ales Imramovsky; Matus Pesko; Katarina Kralova; Marcela Vejsova; Jirina Stolarikova; Jarmila Vinsova; Josef Jampilek
Journal:  Molecules       Date:  2011-03-14       Impact factor: 4.411

9.  Investigating biological activity spectrum for novel styrylquinazoline analogues.

Authors:  Josef Jampilek; Robert Musiol; Jacek Finster; Matus Pesko; James Carroll; Katarina Kralova; Marcela Vejsova; Jim O'Mahony; Aidan Coffey; Jiri Dohnal; Jaroslaw Polanski
Journal:  Molecules       Date:  2009-10-23       Impact factor: 4.411

10.  Investigation of the biological properties of (hetero)aromatic thiosemicarbazones.

Authors:  Maciej Serda; Anna Mrozek-Wilczkiewicz; Josef Jampilek; Matus Pesko; Katarina Kralova; Marcela Vejsova; Robert Musiol; Alicja Ratuszna; Jaroslaw Polanski
Journal:  Molecules       Date:  2012-11-14       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.